Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionDivestmentsDividends Paid - CommonDividends Paid - CommonExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oramed Pharmaceuticals (ORMP) Other Working Capital Changes (2016 - 2026)

Oramed Pharmaceuticals filings provide 16 years of Other Working Capital Changes readings, the most recent being $1.3 million for Q4 2025.

  • Quarterly Other Working Capital Changes rose 284.45% to $1.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $998000.0 through Dec 2025, up 180.34% year-over-year, with the annual reading at $998000.0 for FY2025, 400.14% up from the prior year.
  • Other Working Capital Changes hit $1.3 million in Q4 2025 for Oramed Pharmaceuticals, down from $1.7 million in the prior quarter.
  • Across five years, Other Working Capital Changes topped out at $1.7 million in Q3 2025 and bottomed at -$1.3 million in Q2 2025.
  • Average Other Working Capital Changes over 5 years is $13600.0, with a median of $28500.0 recorded in 2023.
  • Peak annual rise in Other Working Capital Changes hit 7452.17% in 2025, while the deepest fall reached 3351.22% in 2025.
  • Oramed Pharmaceuticals' Other Working Capital Changes stood at -$674000.0 in 2021, then skyrocketed by 247.77% to $996000.0 in 2022, then crashed by 51.0% to $488000.0 in 2023, then plummeted by 32.79% to $328000.0 in 2024, then skyrocketed by 284.45% to $1.3 million in 2025.
  • Per Business Quant, the three most recent readings for ORMP's Other Working Capital Changes are $1.3 million (Q4 2025), $1.7 million (Q3 2025), and -$1.3 million (Q2 2025).